4//SEC Filing
GOODMAN COREY S 4
Accession 0000905148-24-001964
CIK 0001817241other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 8:26 PM ET
Size
20.9 KB
Accession
0000905148-24-001964
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2024-07-22+214,692→ 1,058,284 total - Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,936,637 total - Conversion
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total→ Common Stock (843,592 underlying) - Conversion
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total→ Common Stock (214,692 underlying) - Conversion
Common Stock
2024-07-22+843,592→ 843,592 total - Other
Common Stock
2024-07-22+461,687→ 1,519,971 total
VENBIO GLOBAL STRATEGIC GP III, LTD
10% Owner
Transactions
- Conversion
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total→ Common Stock (214,692 underlying) - Conversion
Common Stock
2024-07-22+214,692→ 1,058,284 total - Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,936,637 total - Other
Common Stock
2024-07-22+461,687→ 1,519,971 total - Conversion
Common Stock
2024-07-22+843,592→ 843,592 total - Conversion
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total→ Common Stock (843,592 underlying)
Adelman Robert J
10% Owner
Transactions
- Conversion
Common Stock
2024-07-22+214,692→ 1,058,284 total - Other
Common Stock
2024-07-22+461,687→ 1,519,971 total - Conversion
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total→ Common Stock (843,592 underlying) - Conversion
Common Stock
2024-07-22+843,592→ 843,592 total - Conversion
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total→ Common Stock (214,692 underlying) - Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,936,637 total
VENBIO GLOBAL STRATEGIC GP III, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,936,637 total - Conversion
Common Stock
2024-07-22+214,692→ 1,058,284 total - Other
Common Stock
2024-07-22+461,687→ 1,519,971 total - Conversion
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total→ Common Stock (843,592 underlying) - Conversion
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total→ Common Stock (214,692 underlying) - Conversion
Common Stock
2024-07-22+843,592→ 843,592 total
GOODMAN COREY S
10% Owner
Transactions
- Conversion
Common Stock
2024-07-22+214,692→ 1,058,284 total - Conversion
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total→ Common Stock (214,692 underlying) - Other
Common Stock
2024-07-22+461,687→ 1,519,971 total - Conversion
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total→ Common Stock (843,592 underlying) - Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,936,637 total - Conversion
Common Stock
2024-07-22+843,592→ 843,592 total
Footnotes (3)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
- [F2]These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein.
- [F3]Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20.
Documents
Issuer
Artiva Biotherapeutics, Inc.
CIK 0001817241
Entity typeother
Related Parties
1- filerCIK 0001278411
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 8:26 PM ET
- Size
- 20.9 KB